NCT07061535 - Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2027

Conditions

Extensive-stage Small Cell Lung Cancer (ES-SCLC)Extensive Stage Lung Small Cell CancerExtensive-Stage Small-Cell Lung CancerExtensive Disease Small Cell Lung Cancer

Interventions

DRUG

Tafolecimab

Patients will receive Tafolecimab 300 mg every 3 weeks.

DRUG

Sintilimab (approved)

Patients will receive Sintilimab 200 mg every 3 weeks.

DRUG

Etoposide

Patients will recieve Etoposide (100 mg/m2) intravenously on days 1, 2, and 3 of each 3-week cycle.

DRUG

Carboplatin / Cisplatin

Patients will receive carboplatin (AUC 5 mg/mL/min) or cisplatin (75 mg/m2) intravenously on day 1 of each 3-week cycle for up to 4 to 6 cycles.

Trial Locations (5)

Unknown

Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha

Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan

Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou

First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou